Medicus Pharma Consolidates Leadership with Mehmud as Antev CEO
Event summary
- Dr. Faisal Mehmud appointed CEO of Antev Limited, Medicus Pharma's UK subsidiary, effective August 30, 2026.
- Mehmud retains role as Chief Medical Officer and Co-Chairman of Antev, consolidating scientific leadership.
- Succeeds Amit Kohli, who served as interim CEO since Antev’s acquisition on August 29, 2025.
The big picture
Medicus Pharma is centralizing leadership to streamline Teverelix’s global development, a critical move as the biotech seeks strategic partners for its pipeline. The appointment underscores the company’s push toward regulatory milestones and commercialization readiness in competitive urologic and women’s health markets.
What we're watching
- Execution Risk
- Whether Mehmud can accelerate Teverelix’s late-stage clinical development and regulatory approvals.
- Strategic Partnering
- The pace at which Medicus secures partnerships for Teverelix amid heightened leadership focus.
- Leadership Continuity
- How Mehmud balances dual roles as Antev CEO and Medicus Chief Medical Officer without operational friction.
Related topics